This round is no longer accepting investments, but hundreds just like it are live now.

Log In


An on-demand personalized implant manufacturing infrastructure

A.D.A.M. develops an on-demand personalized implant manufacturing infrastructure with a full scope of related services, provided remotely or on site.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$134,063.28 Raised


Disrupt a growing market: The orthopedic implants market is expected to reach $79.5 billion in 2030.

Support innovation: A.D.A.M. leading the way in orthopaedics implant production with 3D printing methods.

Improve production times: Competitors in the implant industry have an average 2-4 weeks delivery time, while we are aiming to offer 1-3 day delivery.


Implant manufacturing, one 3D print at a time

A.D.A.M. (Advanced Development of Additive Manufacturing) is a developer of an on-demand personalized implant manufacturing infrastructure with a full scope of related services, provided remotely or on site.  

Currently in the Research and Development stage, A.D.A.M. is designing for medical professionals to complete all steps of the implant printing process from 3D-modeling to receiving a sterilized personalized device, ready for implantation. As a pre-revenue company, A.D.A.M. has identified potential growth opportunities in the orthopaedic surgery, oncology, and CMF, neuro-, and plastic surgery markets.

The company has developed MVP for its printer, materials, digital platform, and has a Quality Management System in place. The company is about to start the animal trials as per the FDA requirements.


Implants are costly and invasive

Many professionals are rethinking global healthcare models due to COVID-19. The basic demand for materials (such as human tissue and organs) remains largely unmet due to supply chain vulnerabilities. The orthopaedic market is currently dominated by titanium implants, which are costlyhave long delivery times, are rarely personalized to the needs of the patients, and typically require a second surgery to extract internal metal fixation.

*Images are computer generated demo versions. Product is still currently under development.


Bone implants made from 3D printing methods

A.D.A.M.’s platform consists of bone implants, printers, materials, digital platform, and our Quality Management System. We create 3D bone implants from ceramic bio-glass for flat bone implants using a Binder Jetting Printing (BJP) method. For tubular bone implants, we use modified biopolymer with a Fused Filament Fabrication (FFF) printing method. The overall production time for us to develop a 3D implant will take up to 24 hours.

*Image is computer generated demo versions. 

Our process

1. Implant modeling: Patients or healthcare providers upload and securely store MRI and CAT scans on our digital platform.  

2. Implant production: Certified clinicians use the platform to create a 3D model of the implant based on the patient's medical data.

3. Implantation: Medical professionals receive a sterilized 3D printed bone implant ready for use and a set of Quality Management System procedures.

4. Recovery: There is no need for reoperation to extract implant elements. Our bone implants are biodegradable, stimulate osteogenesis, and are fully replaced by the bone tissue over time.


Disrupting a market over $47 billion

Our target markets are orthopaedic surgery, oncology, and CMF, neuro-, and plastic surgery. The orthopaedic implants market is estimated at $47 billion for 2019, and expected to reach $79.5 billion in 2030 due to an aging population and an augmented incidence of orthopaedic diseases.

Based on our internal research, competitors in the implant industry have long delivery times of at least 2 to 4 weeks on average, whereas we plan to offer 1-3 day delivery. We are able to keep production costs low because of our material composites and 3D printing methods.

Most competitors offer implants made of either biopolymer or bioceramic implants, while we offer both. The market leader OPM does not offer biodegradable materials at all.


FDA clearance by 2022

In August 2020, FDA confirmed 510(k) eligibility for A.D.A.M. biopolymer and bioceramic bone implants. We have 4 provisional patents (2 for materials and 2 for printers) in the U.S., along with 2 patents for materials in Ukraine.

A.D.A.M. plans to complete the animal studies required by the FDA in 2022. No human trials are required. FDA clearance is expected in late 2022 - early 2023.


A.D.A.M prides ourselves on the established team of advisors we have put together. Our Advisory Board consists of top minds in orthopaedics, material science and 3D printing, chemistry, innovations development, business and digital strategy. 

With calibre of people such as former DARPA director, a top strategy advisor for Secretary of Defense and NATO, to name a few, we are collectively ready to disrupt the health care and 3D printing industry on a scale.


A path to growth

A.D.A.M.’s product has unique characteristics that we believe no other company in the industry has. Bone implants are just the beginning - in the years to come A.D.A.M. aims to launch R&D of blood vessel implants, heart valves, and bronchial implants.

*Image is computer generated demo versions. 

Insert Video


9 W Broad St, Suite 320H
Stamford, CT 06902

A.D.A.M. develops an on-demand personalized implant manufacturing infrastructure with a full scope of related services, provided remotely or on site.


Denys Gurak
Denys Gurak

Denys is a former top executive of industrial conglomerates and an expert in global medical trials regulations. He has extensive experience in management and business development, having worked across the gamut of small technology ventures to industrial and government departments, and his qualifications include Master of Law, an MBA, and Master of Public Administration A member of several think tanks and NGOs, Denys holds a deep passion for world-changing technology. 

Ada Bovsunovsky

Ada Bovsunovsky

Chief Operating Officer

Ada is a former venture fund analyst and has previously interned as a research analyst at a major European hedge fund. She has a BA in Economics (Boston University) and MSc in Finance (Bocconi University). As an analyst, she assisted biotech startups to build their financial models, develop investment materials and attract further financing.

Markian Silecky

Markian Silecky

General Counsel

Markian is a Corporate Counsel with over thirty years of international experience. He is a corporate attorney, co-founder of multiple multinational entities, and former Partner with Dentons. Markian specializes in general corporate law, mergers and acquisitions, and international transactions. 

Arkadii Bohdan MD

Arkadii Bohdan MD

Head of R&D

A Doctor of Medicine (MD), Arkadii graduated from the Odesa National Medical University and is a practicing surgeon. He is a materials patents author, a researcher in 3D bioprinting, and one of the longest-serving employees of A.D.A.M. As Head of R&D, Arkadii is responsible for medical planning, design, material choice, patents, production, and trials of the bone and tissue implants. 

Michael Pluzhnyk

Michael Pluzhnyk

R&D Project Manager

Research & Development Team Project Manager Michael is an engineer focusing on thermal processing and materials chemistry. Previously he was an R&D engineer for 3D printing ceramics, and as a ceramics specialist also lectured in the subject at the prestigious Southukrainian National State Pedagogical University. 

Yuliya Shapovalova

Yuliya Shapovalova

Head of Ukraine Office & Legal Counsel

Yuliya graduated from Donetsk National University with a degree in law, specializing in jurisprudence. A legal adviser and project manager, she has extensive experience working with governments, large enterprises, and IT startups. Yuliya is a Partner at Digital Lawyers Ltd.

Dmytro Skomorokhov

Dmytro Skomorokhov

Business Development Manager

Dmytro is a 3D-printing industry expert, having been involved in sales, business development, and advisory positions for several 3D printing companies. He has a Masters in Law, and has advised Stanley Black & Decker in relation to launching the International Additive Manufacturing Center, opening 2024 in Connecticut. 


May 1, 2022
$10k - $1.07M
Preferred Stock
Series A Preferred Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

Please refer to the Company Securities section of the Offering Memorandum for further details regarding the Series A Preffered Stock rights for the securities sold in this offering.

*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Investment Incentives and Bonuses*


Friends and Family Early Birds

Invest within the first 72 hours and receive additional 15% bonus shares.


Super Early Bird Bonus

Invest within the next 72 hours and receive additional 10% bonus shares.


Early Bird Bonus

Invest within the next 7 days and receive an additional 5% bonus shares.



Perk: 2% Bonus Shares


Perk: 3% Bonus Shares


Perk: 5% Bonus Shares


Perk: 10% Bonus Shares

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Advanced Development of Additive Manufacturing, Inc.'s will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Series A Preferred Stock at $2.93 / share, you will receive 110 Series A Preferred Stock, meaning you'll own 110 shares for $293. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Inter company debt or back payments. Vendor payments. Salary payments made to one’s self, a friend or relative.


Article Image
And the Winners of Startup Grind’s First Ever Global Pitch Battle Are…

Startup Grind hosted its first-ever virtual Global Pitch Battle Competition in late September 2020 where startups from all around the world battled it out to win amazing prizes, global recognition, and of course, bragging rights.

Article Image
FDA Confirms 510(K) Eligibility for Biotech Company A.D.A.M. – 3D Printed Bones Are to Become a Reality in Less Than 2 Years

In recent months, Global healthcare system problems have become strikingly evident. The outbreak of COVID-19 has exacerbated existing issues in the industry, causing many professionals to rethink the healthcare models currently in place.

Article Image
Entering Altered Carbon: A.D.A.M. – Developers of Personalized Implant Printing

Science fiction and Hollywood TV series are becoming a reality thanks to Ukrainian technology startups such as A.D.A.M., which helps customers print new organs, bones, or tissue on a 3D printer.

Article Image
A First Look at 3D Printed Bioresorbable Bone Implants From A.D.A.M.

A.D.A.M. is on the cusp of releasing 3D printed bioresorbable bone implants. The implants would, if successful, be completely absorbed by the body. Recovery times would improve; patients would undergo fewer surgeries; the implant is personalized to each patient.

Article Image
The Economist

What next? 22 emerging technologies to watch in 2022



Last Chance: The A.D.A.M. Investment Opportunity Closes Tomorrow - Don’t Miss Out!

There are only 24 hours left to join the biotech startup named by The Economist as one of the "Emerging Technologies to Watch in 2022.”

According to the FDA, the Covid-19 pandemic has only emphasized the need for 3D printing in healthcare. A.D.A.M. has developed a robust implant-care system that is set to revolutionize the market with 3D printed biotech, offering a new era in orthopaedic healthcare. 

With the orthopaedic implants market expected to reach $79.5 billion in 2030, don’t miss this opportunity to invest in and own part of A.D.A.M. now. 

A.D.A.M. has been marking numerous milestones and highlights, including;

  • We recently announced our partnership with the Mount Sinai Innovation Partners incubator program, providing a clear path for commercialization of our technology in the US

  • We passed pre-clinical trials in accordance with ISO standards, with results submitted to the FDA 

  • This resulted in the FDA confirming in August 2020 the 510(k) eligibility for A.D.A.M. biopolymer and bioceramic bone implants

  • A.D.A.M. has developed proprietary printing materials, holding several patents for materials and printers, including two published PCT patents for materials (US), and two provisional patents for printers (US)

  • We have passed several mechanical tests with Yale Medicine and the University of Connecticut

  • We’ve been featured in numerous publications, articles, broadcast features, interviews, panels, and innovation shortlists 

With the orthopaedics market predicted to grow exponentially, now is the time to join one of the premiere biotech companies in this space.

Haven't invested yet? This is your last chance before the StartEngine campaign closes tomorrow. Join us now as we are poised for continued growth and success!


Ending Soon: Don’t Miss Your Chance To Invest In A Venture Heralding The Future Of Regenerative Medicine

We are very excited to announce that within the span of just a few months, A.D.A.M. has gained over 150 investors. 

Our crowdfunding campaign is ending in just three days, so act now to invest and own a part of one of the “emerging technologies to watch in 2022” (The Economist). 

Need a refresher about what we’re building?

Founded in 2018, A.D.A.M. (Advanced Development of Additive Manufacturing) has created proprietary 3D printing technology and material composites to print personalized bone implants. Our approach to implant manufacturing – using 3D printing – offers a cost-effective production process whilst maintaining implant integrity and quality. 

An alternative to the titanium counterparts prevailing in the market today (e.g. titanium hip implants), A.D.A.M.'s biodegradable and bioresorbable implants are not only easier and more affordable to produce, they also support the progressive development of tissue engineering for improved surgical results. 

Made with material composites including modified bio-polymers, the implants stimulate osteogenesis, meaning they are fully replaced by the bone tissue over time. Therefore, there is no need for reoperation to extract metal fixation elements (comparatively, titanium implants need to be surgically replaced every ten to twenty years).

"With A.D.A.M.’s innovative approach, bones are just the beginning," shares CEO Denys Gurak. "A.D.A.M. has plans to expand into production of other tissues, and thus establish a movement to overcome body limits and open new horizons for healthcare”. 

"The standardization of technology and the practical implementation of artificial tissue production will open the way to the future of regenerative medicine as an industry.” 

With our equity crowdfunding campaign ending this Saturday 30th April, join now to be a part of the future of medicine. 

All photos taken in the A.D.A.M. Research & Development lab 


How Medical Implant Cost Effects Medicine and Treatments

As medical implant technology has continued to grow and Orthopedics has become more specialized, the cost of medical implants has also increased. This is particularly apparent in the Orthopedic implant market. Expenses for Orthopedic implants have risen faster than almost any other type of implant. While this price rise may initially seem concerning, it is essential to understand why these costs are increasing and how they affect both patients and the medical industry. In this blog post, we will explore the reasons for rising implant prices and examine how they impact both patients and doctors.

Orthopedic implants are growing more expensive, but they are also becoming more specialized. In the past, Orthopedic implants were primarily used to replace joints or bones damaged by trauma. However, Orthopedics has since become a highly specialized field, and Orthopedic implants are now used to treat various conditions, from congenital deformities to degenerative diseases. As Orthopedics has become more specialized, the cost of Orthopedic implants has increased.

One reason for the increasing cost of Orthopedic implants is the development of new technology. To treat more complex conditions, Orthopedic surgeons require ever-more sophisticated implants. The development of new Orthopedic technologies is a costly process, and these costs are passed on to patients in the form of higher prices. In addition, Orthopedic implants are often made from expensive materials, such as titanium or stainless steel. These materials must be carefully machined to meet the precise specifications required for Orthopedic surgery.

The Big Struggle In The Implant Industry

The health care system spends a lot of money on implants, but the prices are still too high. There's no way for hospitals or other suppliers to track their inventory correctly, so they often lose products and have patients pay more than necessary because those losses add up fast. Implementing effective supply management practices such as proper tracking techniques can solve this problem without requiring costly last-minute transportation solutions, which everyone involved - manufacturers/suppliers and healthcare providers- would benefit from.

The current struggles faced by hospitals when trying to control costs associated with surgery only makes these problems worse: there have been numerous instances where usable implant inventories were poorly tracked, resulting in higher rates of surgical site infections, unplanned readmissions, and other postoperative complications. To solve this problem, Orthopedic surgeons require ever-more sophisticated implants. The development of new Orthopedic technologies is a costly process, and these costs are passed on to patients in the form of higher prices.

A.D.A.M Changes The Playing Field in Implant Technology

A.D.A.M. (Advanced Development of Additive Manufacturing) is an innovative 3D implant manufacturing biotech recently named one of the "emerging technologies to watch in 2022" by the Economist. A.D.A.M's technology will allow for the customization of implants, which is a huge shift in the Orthopedic industry as it has long relied on "one size fits all" solutions.

The ability to produce implants specific to each patient will have several benefits. First, it will allow Orthopedic surgeons to treat patients with conditions previously considered untreatable. Second, it will reduce the risk of complications associated with Orthopedic surgery. Third, it will lower the cost of Orthopedic implants. A.D.A.M's technology is still in its early stages, but it has the potential to revolutionize Orthopedics and make Orthopedic surgery more accessible and less expensive for everyone.

Denys Gurak founded A.D.A.M. as an innovative solution to traditional titanium bone implants that are costlier, time-consuming, and invasive. The 3D-printed bone implants by A.D.A.M are made using biopolymer, making them highly personalized for patients and eliminating the need to have revision surgery for extraction, resulting in reduced cost and hospital stay.



CEO Denys Gurak Announces Acceptance into Mount Sinai Innovation Partners Incubation Program

Dear investors and followers, 

Today I have a bittersweet update. 

In exceptional news, A.D.A.M. has an exciting development to share  -  we were accepted to the Mount Sinai Innovation Partners incubator program, Elementa Labs in New York City, USA.

Why is this bittersweet? Because this means that we are less reliant on our fundraising efforts through StartEngine.  So, if you have been considering investing in A.D.A.M. and our technology, now is the time to do so. 

Mount Sinai Innovation Partners program means we will be exploring ways to advance and commercialize our core technology platform with the Mount Sinai, a top-rated health system in the US and worldwide. 

Mount Sinai leadership team was particularly supportive when the war in Ukraine started, offering the R&D Department to relocate to NYC from Odesa, Ukraine, and we are considering this one of the options. 

Our StartEngine campaign will be closing on April 30th, so you only have two weeks to join as an investor. 

To invest now, or find out more, simply check out our StartEngine page. I look forward to welcoming you on board. 


Denys Gurak


Orthopedics Equipment: What You Need to Know About Common Procedures

Orthopedics Equipment: What You Need to Know About Common Procedures

Orthopedics is a branch of medicine that deals with the diagnosis and treatment of injuries and disorders of the musculoskeletal system. This includes everything from fractures and dislocations to arthritis and sports injuries. In order to properly treat orthopedic conditions, doctors rely on specialized equipment. In this blog post, we will look at some of the most common orthopedic procedures and the equipment used to perform them.

A.D.A.M will provide an on-demand, personalized implant manufacturing infrastructure with related services that can be provided remotely or at a facility via a full scope of capabilities designed to make this process more efficient for both patients and providers alike.

3D Printing in Orthopedic Surgery

The use of 3D printing in Orthopedic surgery has been a major development that allows for an easier and quicker treatment time when compared with traditional methods. The first approval from FDA came about because this technology allowed doctors to replace metal crowns, which were previously used on teeth as replacements due largely to their durability but also sometimes resulted in too much wear over the years down the line before replacement is needed again--a process taking hours or days depending on how complex your condition may be.

This technology has also been used in the orthopedic field to create trabecular metal (TBM) scaffolds used as an alternative to autologous bone grafts. TBM scaffolds are still relatively new, but they have shown great promise in helping patients heal from orthopedic injuries and disorders.

Some of the most Common Procedures

The list of orthopedic surgeries is extensive, and each one addresses a different part or aspect in the body. While they're still invasive procedures with the potential for complications, many people consider these normal activities given how routine it has become over time.

Some of the most common procedures include:

  • Knee Replacement Surgery
  • ACL Surgery
  • Hip Replacement Surgery
  • Shoulder Replacement Surgery
  • Joint Fusions
  • Shoulder Arthroscopy
  • Knee Arthroscopy

Many of the surgeries mentioned have some form of titanium implant used in them. As discussed in a previous post, there are many problems with titanium. The majority of titanium orthopedic implants today are costly, rarely customized, and require a second surgery to remove metal fixations.

The next generation of orthopedic implants will be made with biocompatible materials that are patient-specific and can be printed on demand. This will allow for better outcomes, shorter surgery times, and reduced implant costs.

A.D.A.M is Moving Ortho Implants into the Future

3D printing is an incredible technology that has revolutionized our lives, work, and play. It's also improved implants for those who need prosthetics or orthopedic implants. A.D.A.M focuses on providing doctors with high-quality medical-grade plastic materials so their patients can get back up again quickly after surgery without having any negative effect long term health-wise due to its biodegradable properties, unlike other alternatives out there, such as polysulfone, which causes inflammation and at worst leaves you needing another operation because it isn't functioning the way it should.

The company started with the idea that any part of your body could be replaced, much like how cars are serviced. The team worked on bone implants and developed proprietary 3D printing technology; they also used materials composites to craft an implantable ceramic shell around it, so you don't need metal plates or other hardware.

This innovation in orthopedic implants is just one way that A.D.A.M is moving ortho implants into the future. To learn more about our company and what we do, visit our website or contact us today. We would be happy to answer any questions you may have.


New Closing Date

Thank you for your investment and for joining us on our journey. Our campaign will be ending early with a new closing date of 4/30/22. We will continue to accept commitments until then and investors who have made commitments will have up to 48 hours before the new deadline to cancel their commitments.


CEO speaks at a 3D printing conference

Curious to learn about the business model behind point of care 3D printing?

Our CEO Denys Gurak was recently a guest speaker at the 2022 3D Bioprinting Conference, hosted in the Netherlands and online

Denys spoke in depth about the new business models in healthcare; you can watch Denys' presentation here


The State of Medical Device Manufacturing: How Companies are Succeeding

Medical device manufacturing is a booming industry. Companies invest billions of dollars in research and development to create cutting-edge medical devices with multiple applications. Orthopedics, implants, bone graft substitutes, tissue engineering, and regenerative medicine are just some segments that are seeing significant growth. This article will look at some of the strategies that companies are using to succeed in this competitive market.

Some of the Different Strategies

One strategy that companies are using is securing FDA approvals. This gives them a competitive edge, as it assures customers that the products are safe and effective. Another strategy is acquisitions/partnership agreements. These can take many different forms, such as joint ventures, collaborations, or expansions into new markets. By doing this, companies can expand globally while also securing intellectual property rights that will protect their investments long term.

Finally, companies invest in research and development to create new and innovative products. This is essential for staying ahead of the competition and keeping up with the latest trends in the industry. Implants and bone graft substitutes have seen a boom in recent years as there's been a heavy focus on new materials. One reason for this is that orthopedic devices are becoming increasingly sophisticated. They can now perform multiple functions, such as restoring joint function and repairing bone defects.

The Growing Use of Biocomposite Materials in Medical Devices

One of the materials that are seeing a lot of growth in the medical device industry is biocomposite materials. These are made from natural fibers and resins, which gives them many advantages over traditional plastics. They are biocompatible, meaning that they are safe for use in the body. They are also environmentally friendly, as they can be recycled and are not harmful to the environment.

Finally, they have excellent mechanical properties. This makes them ideal for use in medical devices, as they can withstand the stresses and strains that are placed on them. Biocomposite materials are already being used in several medical devices, including orthopedic implants and bone graft substitutes. As the industry grows, we can expect to see them being used in even more devices.

Biocomposite materials could be a combination of biphasic calcium phosphate and PLDLA, for one example. Biomaterials are materials that have been designed to substitute for human tissue and provide a function where it is not normally found in the body or has been damaged. Orthopedic biomaterials can be used as components of devices used in joint replacement surgeries, bone repair systems or even guided surgical procedures when necessary.

A.D.A.M, The Next Generation in Medical Devices

The A.D.A.M team has been at the forefront of new technology in bringing patients back into their full range of motion with 3D printing and material composites, which allows them to produce customized implants without sacrificing quality or cost-effectiveness. The orthopedic devices market is growing and changing rapidly, with an increasing demand for implants that can be customized to individual patients.

A.D.A.M has responded to this demand by developing a new generation of medical devices made from advanced composites using additive manufacturing technology (AM). This allows them to produce customized implants without sacrificing quality or cost-effectiveness. They can also produce them much more quickly, which is essential in a constantly changing market.

The A.D.A.M bone implants are a safe and natural way to stimulate osteogenesis. Over time, these bio-based products will be fully replaced by your tissue, meaning there's no need for additional procedures, extraction, or replacement of individual pieces (which could cause pain).


A.D.A.M. Video Update on Operations During Russia’s War on Ukraine


Orthopedic Implants: A Quick Overview of Their Uses

Orthopedic implants are devices that are used to replace or support injured or diseased bone. Orthopedic implants can be made from a variety of materials, including metals, plastics, and ceramics. They are used to treat a wide variety of conditions, including fractures, arthritis, and spinal deformities. In this blog post, we will give a brief overview of the different types of orthopedic implants and their uses.

There are three main types of orthopedic implants:

- Joint replacements. Joint replacements are used to replace a damaged joint, such as a hip or knee joint.

- Spinal implants. Spinal implants are used to support the spine and treat conditions such as spinal deformities and fractures.

- Orthopedic trauma devices. Orthopedic trauma devices are used to treat fractures and other injuries.

Other orthopedic implants include devices for tissue fixation to bone such as suture anchors and screws for ligament reattachment and are made from a variety of materials, including metals, plastics, ceramics, and more recently biological materials that can assist in bone growth. The type of material used depends on the specific injury or condition being treated. For example, metal implants are often used for joint replacements because they are strong and durable. However, plastic or ceramic implants may be used for some spinal conditions because they provide better stability and support.

Orthopedic implants can be placed surgically or nonsurgically. Surgical placement is usually necessary for joint replacements, sports-related injuries, trauma injuries, and some spinal conditions. Orthopedic implants can be permanent or removable depending on many factors. Orthopedic implants are an important part of treating many injuries and conditions. They can help improve function and quality of life.

New Materials and Advancements

Orthopedic implants are made from highly developed materials that require extensive testing before they can be used in an orthokinetic implant. The most common types have had great success in clinical trials and proven successful outcomes. Orthopedic implants are also available in different sizes, shapes, and colors to better match the surrounding tissue. In some cases, the implant may be made from a patient's own cells or tissues to reduce the risk of rejection.

Advancements in surgical techniques have also helped improve outcomes for patients who receive orthopedic implants. For example, minimally invasive surgery can help reduce recovery time and scarring. Orthopedic surgeons are constantly working to develop new materials and surgical techniques to improve the safety and effectiveness of orthopedic implants. Orthopedic implants are an important part of treating many injuries and conditions. They can help improve function and quality of life. New materials and advancements continue to make orthopedic implants more effective.

A.D.A.M Ushers in A New Era

A.D.A.M, which uses proprietary 3D printing technology and material composites to manufacture implants, is at the forefront of new technology in the mission to restore the range of motion for patients seeking treatment.  A.D.A.M. 's exclusive approach to implant manufacturing – using 3D printing – lets enhanced production of personalized implants that are cost-effective and quickly delivered without compromising on the quality.

Amid the COVID-19 pandemic and the need to restructure processes, basic needs for materials (such as human tissue, organs, and titanium implants that dominate the market) are not being met. A.D.A.M. 3D-printed implants are not only more convenient to produce locally, but they also facilitate progress in tissue engineering, so multiple surgeries and implant replacements are not needed.

Its product is unique to the industry and is unlike anything else currently offered, especially at its on-site level. With a burgeoning pipeline, A.D.A.M is looking at additional medical devices such as blood vessel implants, heart valves, and bronchial implants.


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into A.D.A.M..



Michael Nadler


a year ago

When do you actually plan to be pumping out 3-d print molds for individuals? You say you plan to be able to deliver them in a couple days, but when do you plan to start revenues? How far are you from that? Are the 3-d printed molds for individuals the only current plan for revenue stream? I know you plan on different markets, but is this currently the only planned revenue stream? How long do you project animal implants with the fda to take? Is the animal implants for only proof of concept to implant into humans? What's special/unique/proprietary about the company that you believe you'll be able to deliver implants in only 1-3 days? Any patents/protected technology/etc that allows you to do this?



Steven Marks

a year ago

I noticed that alot of the companies footprint is located in the war region of Ukraine. I honestly pray for everyones safety. How does this impact viability of the company and this funding round?



Michael Nadler


a year ago

Interesting that the team aims to deliver implants in 2-4 days. What's the cost structure for the patient? You say that your price is lower than competitors, so walk me through cost as well as how competitor pricing compares.



W Kim Colich


a year ago

Hi Denys, You have stated that you "have 4 provisional patents". When were they filed? When are you planning to file your non-provisional patent applications? Thanks for clarifying this. Blessings



Michael Nadler


a year ago

Denys, you mainly answered my question, but I’m still struggling to understand the uniqueness of Adam vs your competitors you mentioned below. OPM has a 3D orthopedics division on their website. Is there anything unique or proprietary or do you have any patents pertaining to offering both biopolymer and bioceramic materials? Lastly, if particl3d and other companies don’t offer this as a technology as a service, what are they offering? I’m having trouble understanding what your competition does in comparison to Adam. Thanks for your insightful answers.



Michael Nadler


a year ago

Denys, thanks for your through answers. Follow up question- the pitch doesn't address your direct competitors. Can you touch on any current direct competitors in this 3d bone printing/etc space?



Bill Evers

a year ago

One of the people on the A.D.A.M. Advisory Board is Dr. Phillip Karber. An online biography of Dr. Karber indicates that he specializes in military and national-security matters. So, what is Dr. Karber doing for A.D.A.M.? How is his knowledge of military and national-security matters helping A.D.A.M. to develop 3D-printed bones and other body parts? Other members of the Advisory Board are Dr. Anson Ma (professor at UConn), Dr. Mark Horowitz (professor at Yale University School of Medicine), and Dr. Anthony Tether (former director of DARPA and current member of the fund-management team at Ellington Healthcare Partners, a venture-capital fund that invests in start-up companies that produce therapeutic products). So, through these Advisory Board members, A.D.A.M. has connections to UConn, Yale University, DARPA, and Ellington Healthcare Partners. Has A.D.A.M. sought any investments from UConn, Yale University, DARPA, or Ellington Healthcare Partners? I'm guessing that these organizations could invest millions of dollars into A.D.A.M. With all of these connections, why is A.D.A.M. raising money from low-income investors on StartEngine?



Craig Vom Lehn


a year ago

Do you intend to pay a dividend?



Peter Han


a year ago

What is your marketing solutions to have your software and hardware in certified clinics?



Michael Nadler


a year ago

As an interested investor, what's your competitive advantage to a similar company also listed on Start Engine- the company called Monogram seeking almost an $89 mil market valuation with having raised $12 mil so far in their current round and seeking to raise a max of almost $35 mil: What puts adam ahead of the curve compared to this competitor? Thanks.




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team



Important Message


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.